Latest Trials Latest NewsFAQ

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma

Phase 2

Completed

Conditions: Stomach Neoplasms
Esophageal Neoplasms

Interventions: Drug: Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin

First Posted Date: 2006-10-19

Last Posted Date: 2016-03-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 48

Registration Number: NCT00390416

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States

and more 2 locations

Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: umbilical cord blood transplantation
Radiation: total-body irradiation

First Posted Date: 2006-10-13

Last Posted Date: 2016-02-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT00387959

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: decitabine
Drug: tretinoin
Genetic: DNA methylation analysis
Genetic: cytogenetic analysis
Genetic: microarray analysis
Other: flow cytometry
Other: immunohistochemistry staining method

First Posted Date: 2006-09-28

Last Posted Date: 2024-05-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 54

Registration Number: NCT00382200

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery

Not Applicable

Completed

Conditions: Thoracic Surgery

Interventions: Drug: Atorvastatin
Drug: Placebo

First Posted Date: 2006-09-13

Last Posted Date: 2021-01-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 162

Registration Number: NCT00375518

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, New York, United States

Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors

Phase 2

Completed

Conditions: Sarcoma

Interventions: Biological: graft versus host disease prophylaxis/therapy
Drug: busulfan
Drug: melphalan
Drug: thiotepa
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2006-07-27

Last Posted Date: 2015-11-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT00357396

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Biological: bevacizumab
Drug: cisplatin
Drug: irinotecan hydrochloride
Genetic: proteomic profiling
Other: diagnostic laboratory biomarker analysis
Other: mass spectrometry
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery
Radiation: radiation therapy

First Posted Date: 2006-07-20

Last Posted Date: 2016-05-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 34

Registration Number: NCT00354679

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Drug: fluorouracil
Drug: leucovorin calcium
Procedure: conventional surgery
Radiation: radiation therapy
Drug: oxaliplatin
Other: laboratory biomarker analysis
Genetic: DNA analysis
Genetic: polymerase chain reaction
Other: immunohistochemistry staining method

First Posted Date: 2006-06-12

Last Posted Date: 2024-10-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 248

Registration Number: NCT00335816

Locations: 🇺🇸
Cancer Care Center at John Muir Health - Concord Campus, Concord, California, United States
🇺🇸
St. Joseph Hospital Regional Cancer Center - Orange, Orange, California, United States
🇺🇸
Washington Cancer Institute at Washington Hospital Center, Washington, District of Columbia, United States

and more 12 locations

A Randomized Study of Sulindac in Oral Premalignant Lesions

Not Applicable

Completed

Conditions: Leukoplakia, Oral
Benign Neoplasms

Interventions: Drug: sulindac
Drug: Placebo

First Posted Date: 2006-03-06

Last Posted Date: 2020-11-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 63

Registration Number: NCT00299195

Locations: 🇮🇳
Amrita Institute of Sciences (AIMS), Cochin, India
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇮🇳
Regional Cancer Center (RCC), Trivandrum, India

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: rituximab
Drug: bortezomib
Drug: cyclophosphamide
Drug: prednisone

First Posted Date: 2006-02-24

Last Posted Date: 2018-11-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 79

Registration Number: NCT00295932

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 5 locations

Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2005-12-01

Last Posted Date: 2007-01-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT00260026

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy